AU2002335657A1 - Neural regeneration peptide and methods for their use in treatment of brain damage - Google Patents

Neural regeneration peptide and methods for their use in treatment of brain damage

Info

Publication number
AU2002335657A1
AU2002335657A1 AU2002335657A AU2002335657A AU2002335657A1 AU 2002335657 A1 AU2002335657 A1 AU 2002335657A1 AU 2002335657 A AU2002335657 A AU 2002335657A AU 2002335657 A AU2002335657 A AU 2002335657A AU 2002335657 A1 AU2002335657 A1 AU 2002335657A1
Authority
AU
Australia
Prior art keywords
treatment
methods
brain damage
neural regeneration
regeneration peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002335657A
Other languages
English (en)
Other versions
AU2002335657A8 (en
Inventor
Paul Hughes
Frank Sieg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuronz Ltd
NEURONZ BIOSCIENCES Inc
Original Assignee
NEURONZ BIOSCIENCES Inc
Neuronz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEURONZ BIOSCIENCES Inc, Neuronz Ltd filed Critical NEURONZ BIOSCIENCES Inc
Publication of AU2002335657A1 publication Critical patent/AU2002335657A1/en
Publication of AU2002335657A8 publication Critical patent/AU2002335657A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002335657A 2001-08-24 2002-08-22 Neural regeneration peptide and methods for their use in treatment of brain damage Abandoned AU2002335657A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31495201P 2001-08-24 2001-08-24
US60/314,952 2001-08-24
PCT/US2002/026782 WO2003018754A2 (en) 2001-08-24 2002-08-22 Neural regeneration peptide and methods for their use in treatment of brain damage

Publications (2)

Publication Number Publication Date
AU2002335657A1 true AU2002335657A1 (en) 2003-03-10
AU2002335657A8 AU2002335657A8 (en) 2008-01-10

Family

ID=23222205

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002335657A Abandoned AU2002335657A1 (en) 2001-08-24 2002-08-22 Neural regeneration peptide and methods for their use in treatment of brain damage

Country Status (5)

Country Link
US (2) US7767786B2 (enExample)
EP (2) EP2382982A3 (enExample)
JP (1) JP4399260B2 (enExample)
AU (1) AU2002335657A1 (enExample)
WO (1) WO2003018754A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
DE602004029058D1 (de) * 2003-07-09 2010-10-21 Shinonogi & Co Ltd Inducer von atopischer dermatitis
EP1685151A4 (en) * 2003-10-31 2009-04-22 Neuren Pharmaceuticals Ltd PEPTIDES FOR THE REGENERATION OF NERVES AND METHOD FOR THEIR APPLICATION IN THE TREATMENT OF BRAIN DAMAGES
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006121926A2 (en) * 2005-05-06 2006-11-16 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use
HRP20131016T1 (hr) 2007-10-17 2014-01-03 Curonz Holdings Company Limited Sintetiäśki analozi neuralnih regeneracijskih peptida
US9259432B1 (en) 2011-01-31 2016-02-16 Parminder J. S. Vig Composition and methods for targeted delivery of a therapeutic compound to the brain or spinal cord of a subject for treatment of neurodegenerative diseases
US20140018299A1 (en) * 2012-07-10 2014-01-16 Banyan Biomarkers, Inc. Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury
BR112016007816A2 (pt) * 2013-10-11 2017-12-05 Tarix Pharmaceuticals Ltd composições peptídicas inovadoras
CN119080877B (zh) * 2024-10-11 2025-09-23 完美（广东）日用品有限公司 一种低聚肽及其在制备减脂制品中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
WO1995006662A1 (en) * 1993-09-01 1995-03-09 Start Technology Partnership Neuron regulatory factor for promoting neuron survival
EP0756494A1 (en) 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
US5834192A (en) 1996-04-05 1998-11-10 Incyte Pharmaceuticals, Inc. Human cachexia associated protein
WO1998011136A1 (en) 1996-09-09 1998-03-19 Novo Nordisk A/S A cDNA AND PEPTIDE WITH RELATION TO CANCER AND WEIGHT LOSS
HUP0100668A3 (en) * 1997-11-25 2005-01-28 Gen Hospital Corp Boston Virulence-associated nucleic sequences and uses thereof
AU3221399A (en) * 1998-04-03 1999-10-25 Mcp Hahnemann University Neuron regulatory factor comprising a small peptide for promoting neuron survival
US7563862B2 (en) * 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage

Also Published As

Publication number Publication date
AU2002335657A8 (en) 2008-01-10
EP2382982A3 (en) 2012-02-22
US7767786B2 (en) 2010-08-03
EP1572887A4 (en) 2008-12-24
US20030211990A1 (en) 2003-11-13
WO2003018754A2 (en) 2003-03-06
WO2003018754A3 (en) 2007-11-15
EP2382982A2 (en) 2011-11-02
EP1572887A2 (en) 2005-09-14
US20110306557A1 (en) 2011-12-15
JP4399260B2 (ja) 2010-01-13
JP2005511015A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
AU2003286611A1 (en) Cytomodulating peptides and methods for treating neurological disorders
IL160278A0 (en) System and method for face and body treatment
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
IL162505A0 (en) Method for treatment of peripheral neural and vascular ailments
AU2003250059A1 (en) Use of silanes in cosmetic agents and methods for treating hair
AU2001288251A1 (en) Methods and devices for optical stimulation of neural tissues
AU2002335737A1 (en) Systems and methods for removing body tissue
AU2002329562A1 (en) Apparatus for skin enhancement and cellulite reduction
AU2002352483A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
AU2001227898A1 (en) Method and apparatus for stimulating nerve regeneration
AU2002339128A1 (en) Use of reelin, gas6, and protein s in the treatment of neural disorders
AU2003282855A1 (en) Hair treatment system and method
AU2001257069A1 (en) Photostimulaton treatment apparatus and methods for use
AU2002335657A1 (en) Neural regeneration peptide and methods for their use in treatment of brain damage
AU2002316201A1 (en) Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
AU2002338191A1 (en) Surface treatment system and surface treatment method
AU2002340465A1 (en) Cyclo(prolyl-glycine) and methods of use to treat neural disorders
AU2001229471A1 (en) Apparatus and method for hair treatment
AU2003248816A1 (en) Composition for lessening malodors during hair treatment and hair removal and method of use
AU2003244132A8 (en) Method of examining allergic disaese and drug for treating the same
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU2001253886A1 (en) Methylxanthines in the diagnosis and treatment of autistic disorder
AU2002359074A1 (en) Surface treatment system and method
AU2002359061A1 (en) Surface treatment system and method thereof
GB0111441D0 (en) Method and kit for the treatment of cosmetic skin conditions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase